{"id":"ethyl-hydroxybenzoate","rwe":[{"pmid":"41343713","year":"2025","title":"Novel decanoic acid derivatives and 3-farnesyl-p-hydroxybenzoic acid derivatives from the marine fungus Aureobasidium pullulans 8438.","finding":"","journal":"Natural product research","studyType":"Clinical Study"},{"pmid":"41084444","year":"2025","title":"[Study on anti-inflammatory components from Melicope pteleifolia].","finding":"","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica","studyType":"Clinical Study"},{"pmid":"40886820","year":"2025","title":"Preliminary safety risk assessment of parabens in children's cosmetics sold in China.","finding":"","journal":"Regulatory toxicology and pharmacology : RTP","studyType":"Clinical Study"},{"pmid":"40663941","year":"2025","title":"Effects of polyethylene and polypropylene microplastics on the DEP degradation mechanisms initiated by •OH and SO(4)•(-) in aquatic environments.","finding":"","journal":"Ecotoxicology and environmental safety","studyType":"Clinical Study"},{"pmid":"40657954","year":"2025","title":"Coupling Supercritical Fluid Chromatography with Internal Standard Corrected Quantitative NMR for Rapid and Accurate Purity Assessment.","finding":"","journal":"Analytical chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Standardized Chemical Allergen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor beta","category":"target"},{"label":"ESR2","category":"gene"},{"label":"CA2","category":"gene"},{"label":"CA14","category":"gene"},{"label":"D01AE10","category":"atc"},{"label":"Topical","category":"route"},{"label":"Concentrate","category":"form"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mycocten","offLabel":[],"synonyms":["ethyl hydroxybenzoate","ethylparaben","ethyl parasept","mycocten"],"timeline":[],"approvals":[],"brandName":"Mycocten","ecosystem":[],"mechanism":{"target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14","targets":[{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor beta","protein":"Estrogen receptor beta"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA14","source":"DrugCentral","target":"Carbonic anhydrase 14","protein":"Carbonic anhydrase 14"},{"gene":"CA1","source":"DrugCentral","target":"Carbonic anhydrase 1","protein":"Carbonic anhydrase 1"},{"gene":"CA9","source":"DrugCentral","target":"Carbonic anhydrase 9","protein":"Carbonic anhydrase 9"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase 12","protein":"Carbonic anhydrase 12"},{"gene":"CA7","source":"DrugCentral","target":"Carbonic anhydrase 7","protein":"Carbonic anhydrase 7"},{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"}],"modality":"Small Molecule","drugClass":"Standardized Chemical Allergen","explanation":"Think of estrogen receptors like locks on a door. Mycocten is a key that fits into one of these locks, which can affect how cells behave. By binding to estrogen receptor beta, Mycocten may influence the activity of genes that are involved in various physiological processes.","oneSentence":"Mycocten works by binding to estrogen receptor beta, which is a protein that plays a role in various cellular processes.","technicalDetail":"Mycocten's binding to estrogen receptor beta is a competitive process, where it competes with endogenous ligands such as 17β-estradiol for binding to the receptor. This interaction may modulate the transcriptional activity of estrogen receptor beta, leading to changes in gene expression and potentially influencing various physiological processes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ethylparaben","title":"Ethylparaben","extract":"Ethylparaben (ethyl para-hydroxybenzoate) is the ethyl ester of p-hydroxybenzoic acid. Its formula is HO-C6H4-CO-O-CH2CH3. It is a member of the class of compounds known as parabens."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4773","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ethyl%20hydroxybenzoate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ethyl hydroxybenzoate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ethylparaben","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T11:08:28.758799","biosimilars":[],"competitors":[{"drugName":"undecylenic acid","drugSlug":"undecylenic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorphenesin carbamate","drugSlug":"chlorphenesin-carbamate","fdaApproval":"1965-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"haloprogin","drugSlug":"haloprogin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"selenium sulfide","drugSlug":"selenium-sulfide","fdaApproval":"1951-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclopirox","drugSlug":"ciclopirox","fdaApproval":"1982-12-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"terbinafine","drugSlug":"terbinafine","fdaApproval":"1992-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tolnaftate","drugSlug":"tolnaftate","fdaApproval":"","relationship":"same-class"},{"drugName":"flucytosine","drugSlug":"flucytosine","fdaApproval":"1971-11-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"naftifine","drugSlug":"naftifine","fdaApproval":"1988-02-29","patentExpiry":"Jan 31, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"butenafine","drugSlug":"butenafine","fdaApproval":"1996-10-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tavaborole","drugSlug":"tavaborole","fdaApproval":"2014-07-07","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ethyl hydroxybenzoate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"undecylenic-acid","brandName":"undecylenic acid","genericName":"undecylenic acid","approvalYear":"","relationship":"same-class"},{"drugId":"chlorphenesin-carbamate","brandName":"chlorphenesin carbamate","genericName":"chlorphenesin carbamate","approvalYear":"1965","relationship":"same-class"},{"drugId":"haloprogin","brandName":"haloprogin","genericName":"haloprogin","approvalYear":"","relationship":"same-class"},{"drugId":"selenium-sulfide","brandName":"selenium sulfide","genericName":"selenium sulfide","approvalYear":"1951","relationship":"same-class"},{"drugId":"ciclopirox","brandName":"ciclopirox","genericName":"ciclopirox","approvalYear":"1982","relationship":"same-class"},{"drugId":"terbinafine","brandName":"terbinafine","genericName":"terbinafine","approvalYear":"1992","relationship":"same-class"},{"drugId":"tolnaftate","brandName":"tolnaftate","genericName":"tolnaftate","approvalYear":"","relationship":"same-class"},{"drugId":"flucytosine","brandName":"flucytosine","genericName":"flucytosine","approvalYear":"1971","relationship":"same-class"},{"drugId":"naftifine","brandName":"naftifine","genericName":"naftifine","approvalYear":"1988","relationship":"same-class"},{"drugId":"butenafine","brandName":"butenafine","genericName":"butenafine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":["Prostate Adenocarcinoma"],"enrollment":2050,"completionDate":"2026-11-11"},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":["Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":2753,"completionDate":"2033-12-31"},{"nctId":"NCT00135226","phase":"PHASE4","title":"ASCEND: A Study of Cardiovascular Events iN Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2005-03","conditions":["Diabetes Mellitus"],"enrollment":15480,"completionDate":"2037-07-31"},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":["Coronary Artery Disease","Atherosclerosis","Heart Attack"],"enrollment":0,"completionDate":"2025-01-01"},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":["Post-operative Nausea and Vomiting","Laparoscopic Sleeve Gastrectomy"],"enrollment":83,"completionDate":"2019-04-01"},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":["Postoperative Nausea and Vomiting"],"enrollment":27034,"completionDate":"2017-11-30"},{"nctId":"NCT02545712","phase":"","title":"Safe Excipient Exposure in Neonates and Small ChildreN","status":"UNKNOWN","sponsor":"Bispebjerg Hospital","startDate":"2016-01","conditions":["Excipient Exposure","Neonatal","Pediatric"],"enrollment":630,"completionDate":""},{"nctId":"NCT02410460","phase":"NA","title":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","startDate":"2013-09","conditions":["Rhytidoplasty"],"enrollment":30,"completionDate":"2014-06"},{"nctId":"NCT01160848","phase":"PHASE2","title":"Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients","status":"COMPLETED","sponsor":"Photocure","startDate":"2010-08","conditions":["Acne Vulgaris"],"enrollment":20,"completionDate":"2011-01"},{"nctId":"NCT00771914","phase":"PHASE1,PHASE2","title":"The Effects of Omega-3 Fatty Acids on Aspirin Resistance","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2008-11","conditions":["Increased Drug Resistance"],"enrollment":27,"completionDate":"2009-01"},{"nctId":"NCT01712295","phase":"PHASE4","title":"17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts","status":"UNKNOWN","sponsor":"Grossman, Michael, D.P.M.","startDate":"2011-11","conditions":["Warts"],"enrollment":100,"completionDate":"2014-03"},{"nctId":"NCT00688961","phase":"EARLY_PHASE1","title":"Effects of Omacor and Aspirin on Platelet Function","status":"COMPLETED","sponsor":"Sanford Research","startDate":"2007-06","conditions":["Healthy"],"enrollment":10,"completionDate":"2007-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Concentrate","formulations":[{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona"},{"form":"CONCENTRATE","route":"TOPICAL","productName":"Anubis Barcelona Regul OIl"}]},"crossReferences":{"MMSL":"NOCODE","NDDF":"005164","UNII":"14255EXE39","CHEBI":"CHEBI:88839","RXNORM":"1362892","UMLSCUI":"C3652694","ChEMBL_ID":"CHEMBL15841","DRUGBANK_ID":"DB13628","PDB_CHEM_ID":"E4B","PUBCHEM_CID":"8434","SNOMEDCT_US":"255864002"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":128,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"D01AE10","allCodes":["D01AE10"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 4","pmid":"41343713","title":"Novel decanoic acid derivatives and 3-farnesyl-p-hydroxybenzoic acid derivatives from the marine fungus Aureobasidium pullulans 8438.","journal":"Natural product research"},{"date":"2025 Aug","pmid":"41084444","title":"[Study on anti-inflammatory components from Melicope pteleifolia].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"},{"date":"2025 Dec","pmid":"40886820","title":"Preliminary safety risk assessment of parabens in children's cosmetics sold in China.","journal":"Regulatory toxicology and pharmacology : RTP"},{"date":"2025 Sep 1","pmid":"40663941","title":"Effects of polyethylene and polypropylene microplastics on the DEP degradation mechanisms initiated by •OH and SO(4)•(-) in aquatic environments.","journal":"Ecotoxicology and environmental safety"},{"date":"2025 Jul 22","pmid":"40657954","title":"Coupling Supercritical Fluid Chromatography with Internal Standard Corrected Quantitative NMR for Rapid and Accurate Purity Assessment.","journal":"Analytical chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Mycocten (ethyl hydroxybenzoate) is a small molecule standardized chemical allergen that targets the estrogen receptor beta. Its mechanism of action is not well-documented, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the potential benefits and risks of Mycocten. Its development history is also unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}